ADVFN Logo
Registration Strip Icon for monitor Customized watchlists with full streaming quotes from leading exchanges, such as NASDAQ, NYSE, AMEX, OTC Markets Small-Cap, LSE and more.

NAMS NewAmsterdam Pharma Company NV

18.82
-0.28 (-1.47%)
May 25 2024 - Closed
Delayed by 15 minutes

Period:

Draw Mode:

Volume 131,706
Bid Price 17.63
Ask Price 150.00
News -
Day High 20.3263

Low
5.6326

52 Week Range

High
26.35

Day Low 18.51
Company Name Stock Ticker Symbol Market Type
NewAmsterdam Pharma Company NV NAMS NASDAQ Common Stock
  Price Change Change Percent Stock Price Last Traded
-0.28 -1.47% 18.82 00:00:05
Open Price Low Price High Price Close Price Prev Close
19.11 18.51 20.3263 18.82 19.10
Trades Volume VWAP Dollar Volume Avg Volume 52 Week Range
2,287 131,706 $ 18.89 $ 2,487,860 - 5.6326 - 26.35
Last Trade Time Type Quantity Stock Price Currency
16:02:38 90 $ 19.76 USD

NewAmsterdam Pharma Company NV Financials

Market Cap Shares in Issue Float Revenue Profit/Loss EPS PE Ratio
1.68B 89.27M - 14.09M -176.94M -1.98 -
Short Interest Dividends Per Share Dividend Yield Ex-Div Date Insider B/S Insider % Owned
- - - -

more financials information »

NewAmsterdam Pharma Comp... News

Loading Messages....

{{bbMessage.M_Alias}} {{bbMessage.MSG_Date}} {{bbMessage.HowLongAgo}} {{bbMessage.MSG_ID}} {{bbMessage.MSG_Subject}}

Loading Messages....


No posts yet, be the first! No NAMS Message Board. Create One! See More Posts on NAMS Message Board See More Message Board Posts

Historical NAMS Price Data

Period Open High Low VWAP Avg. Daily Vol Change %
1 Week19.9920.3518.5119.7490,530-1.17-5.85%
1 Month21.1323.0118.5120.98117,734-2.31-10.93%
3 Months23.1624.7918.2221.09174,063-4.34-18.74%
6 Months9.7426.358.9019.20194,5759.0893.22%
1 Year14.2826.355.632615.95150,6574.5431.79%
3 Years11.0032.885.632615.50115,2767.8271.09%
5 Years11.0032.885.632615.50115,2767.8271.09%

NewAmsterdam Pharma Comp... Description

NewAmsterdam Pharma Company N.V., a clinical-stage biopharmaceutical company, develops oral and non-statin medicines for patients at high risk of cardiovascular disease. Its lead product candidate is obicetrapib, a next generation, oral, and low-dose cholesteryl ester transfer protein (CETP) inhibitor, that is in four ongoing Phase 3 and Phase 2b clinical trials as both a monotherapy and a combination therapy with ezetimibe for lowering LDL-C and preventing major adverse cardiovascular events (MACE). NewAmsterdam Pharma Company N.V. is headquartered in Naarden, the Netherlands.

Your Recent History

Delayed Upgrade Clock